Photo of Charles Lavine
D New York Assembly · District 13 On the 2026 ballot

Asm. Charles Lavine

Compare
Total votes
9,713
all sessions
Attendance
98%
218 missed
Near the chamber average
With party
99%
of cast votes
Higher than 77% of chamber peers
Bipartisan score
0%
crosses aisle rarely
Lower than 79% of chamber peers
Sponsored
985
bills & resolutions
Near the chamber average
Committees
5
assignments
985 bills and resolutions

Sponsored bills

Total
985
Primary
310
Co-sponsor
675
This page
985
matching current filters
Primary A 7047
In committee · New York Assembly · Lead sponsor
Relates to timely release of principals on bail

Requires persons held in custody to be released immediately upon posting bail; requires use and acceptance of electronic signatures and records to effectuate communications relating to posting bail.

In committee Jan 3, 2024 0 co-sponsors
Primary A 7386
In committee · New York Assembly · Lead sponsor
Prevents fraudulent deed transfers

Relates to preventing fraudulent deed transfers; protects home owners from being misled into transferring their home to mortgage servicers.

In committee Jan 3, 2024 0 co-sponsors
Primary A 7450
In committee · New York Assembly · Lead sponsor
Relates to applications for enhanced attorneys fees in medical, dental or podiatric malpractice cases

Updates the procedure for applying for attorney's fees in medical, dental or podiatric malpractice cases in excess of the statutory contingent fee schedule in circumstances where the amounts set forth in such fee schedule are inadequate to compensate the attorney for the legal services rendered.

In committee Jan 3, 2024 0 co-sponsors
Co-sponsor A 7465
In committee · New York Assembly · Co-sponsor
Preserves access to affordable drugs

Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.

In committee Jan 3, 2024 1 co-sponsor
Showing 651 to 660 of 985 bills
Previous 1 … 65 66 67 … 99 Next